Target intelligence / Profile preview

Sarcoplasmic reticulum calcium ATPase isoform 2a (SERCA2a)

Target
SERCA2a
Molecular classification
Enzyme, Transporter (specifically, P-type ATPase family)
01

Overview

Sarcoplasmic reticulum calcium ATPase isoform 2a (SERCA2a) is an enzyme encoded by the ATP2A2 gene. It is a magnesium-dependent transmembrane pump responsible for hydrolyzing ATP to actively transport Ca²⁺ ions from the cytosol into the lumen of the sarcoplasmic reticulum in cardiac muscle cells. This process is essential for lowering cytosolic Ca²⁺ during muscle relaxation, refilling SR stores for subsequent contractions, and maintaining proper myocardial function. The activity of SERCA2a is tightly regulated by proteins such as phospholamban and sarcolipin. Decreased expression or dysfunction of SERCA2a impairs cardiac performance and contributes significantly to pathologies such as heart failure[1][3].

Other names
Sarco(endo)plasmic reticulum calcium ATPase 2aATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 (isoform a)ATP2A2 (gene name)Cardiac SERCASR Ca2+ pump (cardiac)
02

Mechanism of action

Drugs or therapies targeting this molecule aim to enhance or restore its activity to improve cardiac contractility by increasing the reuptake of Ca²⁺ into the sarcoplasmic reticulum, thereby improving relaxation and contraction cycles in heart muscle[1][2].

03

Biological functions

Calcium ion transport from cytosol into the sarcoplasmic reticulumRegulation of cytosolic calcium concentration in cardiac muscle cellsControl of myocardial contractility and relaxation[1][2][3]Maintenance of intracellular calcium homeostasis[5]
04

Disease associations

Cardiovascular disease (notably heart failure and cardiomyopathies)[1][2]Other diseases involving abnormal calcium handling in muscle tissue
05

Safety considerations

Potential safety concerns include arrhythmias due to altered intracellular Ca²⁺ cycling if overactivatedoff-target effects with gene therapy approacheschallenges with delivery specificity for therapeutic interventions
06

Interacting drugs

There are no widely approved direct small-molecule drugs targeting SERCA2a, but gene therapy approaches and experimental compounds exist. Drugs that indirectly affect its function include those modulating phospholamban or influencing cardiac contractility.
07

Biomarkers

Reduced expression or activity of SERCA2a is used as a biomarker for heart failure severity and progression[1][2]

Beyond the preview

Go deeper on Sarcoplasmic reticulum calcium ATPase isoform 2a (SERCA2a).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sarcoplasmic reticulum calcium ATPase isoform 2a (SERCA2a).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call